RecruitingPhase 3NCT06051617
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Studying Primary biliary cholangitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gilead Sciences
- Principal Investigator
- Gilead Study DirectorGilead Sciences
- Intervention
- Seladelpar(drug)
- Enrollment
- 318 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2030
Study locations (30)
- St. Joseph's Hospital and Medical Center - 350 W. Thomas, Phoenix, Arizona, United States
- OM Research LLC, Lancaster, California, United States
- SCPMG/Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
- Cedar Sinai Medical Center, Los Angeles, California, United States
- California Liver Research Institute, Pasadena, California, United States
- Stanford University, Redwood City, California, United States
- University of California, Davis Medical Center, Sacramento, California, United States
- California Pacific Medical Center - Sutter Pacific Medical Foundation, San Francisco, California, United States
- Connie Frank Transplant Center at UCSF, San Francisco, California, United States
- Covenant Metabolic Specialists, LLC, Fort Myers, Florida, United States
- Schiff Center for Liver Diseases/University of Miami, Miami, Florida, United States
- Covenant Metabolic Specialists, LLC, Sarasota, Florida, United States
- Florida Research Institute, Tampa, Florida, United States
- Piedmont Atlanta Hospital / Piedmont Transplant Institute, Atlanta, Georgia, United States
- Northwestern University, Chicago, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06051617 on ClinicalTrials.govOther trials for Primary biliary cholangitis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07449793Biochemical Response and Clinical Outcomes in Patients With PBCRenJi Hospital
- RECRUITINGPHASE3NCT07296458FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC TherapyXijing Hospital of Digestive Diseases
- RECRUITINGPHASE3NCT07282353A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCACascade Pharmaceuticals, Inc
- RECRUITINGNCT07205874Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)Hospital Universitario La Paz
- ACTIVE NOT RECRUITINGNCT07049887A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)Ipsen
- RECRUITINGNCT07149675PBC Long-term Outcomes StudyBeijing Friendship Hospital
- RECRUITINGEARLY PHASE1NCT07104201Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)Xijing Hospital of Digestive Diseases
- RECRUITINGNANCT06861465EMPower MechanismsUniversity of Alberta